Oral administration of a novel RORγt antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17

Highlights • We have developed a novel RORγt antagonist, A213. • A213 specifically binds to RORγt and inhibits murine Th17 differentiation in vitro. • Oral administration of A213 attenuates psoriasis-like inflammation in mouse models.

Saved in:
Bibliographic Details
Published in:Journal of dermatological science 2017-01, Vol.85 (1), p.12-19
Main Authors: Takaishi, Mikiro, Ishizaki, Masayuki, Suzuki, Keisuke, Isobe, Takashi, Shimozato, Takaichi, Sano, Shigetoshi
Format: Article
Language:English
Subjects:
Administration, Oral
Animals
Antagonist
Cell Differentiation - drug effects
Cell Line, Tumor
Dermatology
Disease Models, Animal
Humans
Interleukin-17 - metabolism
Interleukin-23 - metabolism
Mice
Mice, Inbred BALB C
Mice, Knockout
Mouse model
Nuclear Receptor Subfamily 1, Group F, Member 3 - antagonists & inhibitors
Nuclear Receptor Subfamily 1, Group F, Member 3 - genetics
Psoriasis
Psoriasis - chemically induced
Psoriasis - drug therapy
Psoriasis - metabolism
Receptors, Interleukin-17
RORγt
Signal Transduction - drug effects
Skin - drug effects
Skin - metabolism
STAT3 Transcription Factor - genetics
STAT3 Transcription Factor - metabolism
Tetradecanoylphorbol Acetate - analogs & derivatives
Tetradecanoylphorbol Acetate - toxicity
Th17
Th17 Cells - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • We have developed a novel RORγt antagonist, A213. • A213 specifically binds to RORγt and inhibits murine Th17 differentiation in vitro. • Oral administration of A213 attenuates psoriasis-like inflammation in mouse models.
ISSN:0923-1811
1873-569X
DOI:10.1016/j.jdermsci.2016.10.001